secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0001628280-22-030866
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Pharma reports FY22 revenue up but net loss widens to $172.7M; $250M royalty sale
--------------------------------------------------------------------------------

- Revenue $243.2M for FY22 (Sep 30 yr-end), up 76% from $138.3M in FY21.
- Net loss $172.7M ($1.67 diluted loss per share) vs $140.8M ($1.36) prior year.
- Sold olpasiran royalty interest to Royalty Pharma for $250M cash plus up to $160M milestones.
- Phase 2 studies for ARO-APOC3 and ARO-ANG3 fully enrolled; new Phase 1/2a starts for ARO-MUC5AC, ARO-RAGE, ARO-MMP7.
- Cash and investments $482.3M at Sep 30, 2022, down from $613.4M at Sep 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828022030866/0001628280-22-030866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828022030866/arwr-20221128.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-030866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer